Abbott Rapid Dx North America LLC Cancer Screening Test Kit NMP22® Bladderchek® Bladder Cancer 24...
| Item Id | 1195469 |
| MF Id# | D1200 |
| Brand | NMP22® Bladderchek® |
| Manufacturer | Abbott Rapid Dx North America LLC |
| Country of Origin | United States |
| Application | Cancer Screening Test Kit |
| CLIA Classification | CLIA Waived |
| CLIA Classified | CLIA Waived |
| Contents 1 | (24) Individually Wrapped Test Devices with Urine Dropper and Desiccant |
| Is_Active_Vendor | Y |
| Is_DSCSA | N |
| Is_Discontinued | N |
| Is_Medical_Device | N |
| Lot_Tracking_Flag | N |
| Number of Tests | 24 Tests |
| On_Allocation | N |
| Product Dating | McKesson Acceptable Dating: we will ship >= 90 days |
| Purchase Program Type | Standard Purchase |
| Reading Type | Visual Read |
| Sample Type | Urine Sample |
| Specialty | Immunoassay |
| Supplier_ID | 64711003 |
| Test Format | Test Device Format |
| Test Kit Type | Rapid |
| Test Name | Bladder Cancer |
| Test Type | Immunoassay |
| Time to Results | 30 Minute Results |
| UNSPSC Code | 41116128 |
Features
- A Rapid Test for the Qualitative Detection of Alere NMP22 Nuclear Matrix Protein in human urine
- The Alere NMP22® BladderChek® Test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (NuMA), which is an abundant component of the nuclear matrix proteins, in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer
- This test is indicated for professional use and prescription home use as an aid in diagnosing and monitoring bladder cancer patients, in conjunction with standard diagnostic procedures
- Each device incorporates colloidal gold particles conjugated to the reporter antibody and a capture monoclonal antibody, immobilized on a membrane; the procedural Control zone contains an immobilized goat anti-mouse IgG-specific antibody